3M's $7.35 Billion PFAS Settlement: What the AFFF Personal Injury Deal Pays, and Who Qualifies

3M's $7.35 billion PFAS settlement, announced on November 3, 2026, is a nine-year, opt-in deal meant to resolve about 99% of current personal injury claims over aqueous film-forming foam (AFFF), covering roughly 115,000 to 120,000 eligible plaintiffs inside and outside MDL No. 2873 in the District of South Carolina. Its present value is $5.8 billion, almost nothing is paid before 2028, and the deal holds only if enough plaintiffs sign full releases, so the money is real but conditional.

The announcement comes two weeks after 3M told investors, on October 20, that it was working with a court-appointed mediator and had no deal to report. It is 3M's third multibillion-dollar mass resolution since 2023, after the public water system settlement approved by Judge Richard M. Gergel in Charleston and the Combat Arms earplug deal in the Northern District of Florida. What follows separates what the company and plaintiffs' leadership have actually disclosed from what remains unknown, and works through what the structure means for claimants, plaintiffs' firms, funders and the defendants still in the case.

The 3M $7.35 billion PFAS settlement at a glance

The deal resolves personal injury claims, not property or water-system claims, brought in or alongside In re Aqueous Film-Forming Foams Products Liability Litigation, the multidistrict litigation the Judicial Panel on Multidistrict Litigation centralized in Charleston before Judge Gergel. The plaintiffs are mostly people who allege that PFAS, the "forever chemicals" in firefighting foam, caused cancers and other diseases after exposure through foam use in firefighting and training exercises or through contaminated drinking water near military bases, airports and fire-training sites.

Term	What has been disclosed
Announced	November 3, 2026 (3M release and Form 8-K)
Nominal amount	$7.35 billion, pre-tax, paid 2026 through 2034
Present value	$5.8 billion
Accounting	About $5.8 billion pre-tax charge in Q4 2026, treated as a special item; 2026 guidance unchanged
Scope	About 99% of current AFFF personal injury claims, inside and outside the MDL
Eligible plaintiffs	About 115,000 to 120,000
Reserve for remaining and future claims	$680 million, included in the $7.35 billion
Release	Full release of PFAS-related personal injury claims against 3M
Liability	No admission of liability or wrongdoing
Walk-away	3M says it will keep defending itself if agreed terms are not met
Court	U.S. District Court for the District of South Carolina, Judge Richard M. Gergel
Plaintiffs' co-lead counsel	Scott Summy (Baron & Budd) and Michael London (Douglas & London)

How much is the 3M PFAS personal injury settlement?

3M has committed $7.35 billion in nominal dollars over nine years, which the company values at $5.8 billion in present-value terms. The gap between the two numbers is the time value of a long, deferred payout: the further out the money sits, the less it is worth today.

The payment curve is the most important structural feature. Reporting on the 8-K and 3M's investor materials shows a $50 million payment in 2026, no payment at all in 2027, and roughly 20% of the total in the final two years of the term. That leaves the large majority, on the order of $5.8 billion in nominal terms by simple subtraction, to fall between 2028 and 2032. 3M said it timed the schedule around its other legacy obligations, chiefly the public water system settlement, which carries heavy payments in the same window.

Period	Payment (nominal)	Source of figure
2026	$50 million	Disclosed
2027	$0	Disclosed
2028 to 2032	About $5.83 billion, combined	Derived: total less 2026 and final-two-year share
2033 to 2034	About 20% of total, roughly $1.47 billion	Disclosed as a percentage
Total	$7.35 billion	Disclosed

Year-by-year amounts for 2028 through 2032 were not in the public announcements this desk could review and are not estimated here.

Investors read the number as a relief. UBS, which kept a Buy rating and a $230 price target, said market expectations had run near $10 billion and called the deal the last major outstanding piece of PFAS litigation for the company. 3M shares rose about 1.1% in after-hours trading on November 3.

Who is eligible for the 3M AFFF settlement?

People with pending or potential AFFF personal injury claims against 3M, inside or outside the MDL, are eligible if they enroll and sign a full release of PFAS-related personal injury claims against the company. 3M estimates the eligible pool at 115,000 to 120,000 plaintiffs.

That figure needs context. 3M's own quarterly report put the number of cases pending on the MDL docket at roughly 15,250 as of October 1, 2026, after court-ordered claims vetting under Case Management Order No. 37 led to tens of thousands of claims being dismissed without prejudice. An eligible pool eight times larger than the docket means most of the people the deal is designed to reach are not, or are not yet, individual docketed cases in Charleston. They include claimants in state courts and claimants whose claims sit outside the MDL docket, which is why 3M framed the deal as covering claims "inside and outside" the MDL. The announcements do not break the pool down further, and that breakdown will matter: a claimant who was dismissed for failing to submit a Plaintiff Fact Sheet or diagnosis records is not automatically outside the program, but will need to meet whatever proof requirements the claims protocol sets.

What injuries qualify for the 3M firefighting foam settlement?

Plaintiffs' co-lead counsel said the settlement compensates six "Eligible Injuries," including kidney cancer and testicular cancer. The MDL's case management orders designated six injuries for the personal injury track, which case trackers report as kidney cancer, testicular cancer, liver cancer, thyroid cancer, thyroid disease and ulcerative colitis. The full settlement agreement, filed as an exhibit to 3M's 8-K, is the controlling document for any injury list and any disease-specific limitations.

Those six injuries track the conditions most often linked to PFOA and PFOS exposure in the epidemiology that has driven the litigation. Claimants alleging other conditions, such as prostate cancer, which some trackers describe as still under evaluation, should not assume coverage until the agreement or a claims protocol says so. Whether the deal reaches the separate group of turnout-gear cases that firefighters have filed in the MDL is not addressed in the public announcements.

How the deal binds: opt-in, releases and the walk-away

This is not a Rule 23 class settlement. Nothing binds a plaintiff who does not affirmatively enroll, and that is why 3M's description leans on participation. Each participant must sign a release, and 3M's 8-K says payments are tied to participation thresholds and that the structure is "structured to promote participation by claimants." If agreed terms are not satisfied, 3M says it is "prepared to continue to defend itself in litigation."

That combination, a private global settlement with an opt-in mechanic and a walk-away right, is now the standard architecture for very large mass tort resolutions. The 2023 Combat Arms earplug deal used the same pattern, and Johnson & Johnson's 2026 talc proposal is conditioned on 95% participation. The practical consequence is that the headline number is a ceiling contingent on enrollment, and the first real test is the participation rate at the deadline the agreement sets. Neither the numeric threshold nor the enrollment deadline was in the public announcements; both should be in the filed agreement.

What happens to AFFF plaintiffs who do not join the 3M settlement?

Plaintiffs who decline can keep litigating, but 3M has signaled they will face a tougher path. The company said remaining and future claims, inside and outside the MDL, will be managed through three tools: payments contingent on plaintiffs joining the resolution, a $680 million reserve fund that is part of the $7.35 billion, and an anticipated order from the MDL court "establishing evidentiary and timing requirements" for plaintiffs who may seek to litigate in the future.

That last element reads as a Lone Pine Order or a close cousin. In MDL practice, such an order requires each non-settling plaintiff to produce, by a set date, case-specific evidence of exposure, diagnosis and expert support for causation, on pain of dismissal. Judge Gergel has already shown a willingness to enforce proof requirements: the CMO 37 vetting process ended with a special master recommending dismissal of most claims targeted in the first rounds of defense motions. A plaintiff who opts out should expect early and expensive work, not a quiet wait for a trial date. No such order had been entered as of November 4.

How much will each AFFF plaintiff get from the 3M settlement?

No per-claimant figure has been disclosed, and no settlement matrix has been published. Individual awards will turn on injury, diagnosis timing, exposure evidence and other factors the claims protocol sets. Simple division gives only a ceiling-style reference point, before attorney fees, case costs, common benefit assessments and liens.

Calculation	Result (nominal, gross)
$7.35 billion less $680 million reserve	$6.67 billion
Divided by 115,000 eligible plaintiffs	About $58,000 each
Divided by 120,000 eligible plaintiffs	About $55,600 each
Present value of $5.8 billion divided by 120,000	About $48,300 each (includes reserve)

These are averages across very different injuries. A matrix will almost certainly weight cancers such as kidney and testicular cancer well above thyroid disease or ulcerative colitis, and the spread around any average will be wide. The payment schedule also matters for real value: a claimant paid in 2032 receives dollars worth less than a claimant paid in 2028.

Is the 3M personal injury deal the same as the $10.3 billion water settlement?

No. The 2023 public water system settlement compensates water utilities for testing and treating drinking water for PFAS; it pays no individuals for illness. Judge Gergel granted final approval on March 29, 2024, valuing 3M's commitment at up to $10.3 billion in present value over 13 years, with nominal payments between $10.5 billion and $12.5 billion. Roughly 7.5% of class water systems opted out.

The new deal is the personal injury counterpart, and it is structured differently: an opt-in private settlement rather than a certified settlement class. Public coverage also notes that it does not resolve community suits seeking cleanup, testing or remediation costs.

3M settlement	Year	Claimants	Headline amount	Structure
Combat Arms earplugs	2023	Service members and veterans with hearing claims	$6 billion	Private opt-in program
Public water systems (AFFF MDL)	2023, approved 2024	About 12,000 public water systems	Up to $10.3 billion PV over 13 years	Rule 23 settlement class
AFFF personal injury (MDL 2873)	2026	About 115,000 to 120,000 individuals	$7.35 billion nominal, $5.8 billion PV, over 9 years	Private opt-in program with thresholds

Does the 3M settlement cover DuPont, Chemours, or other AFFF defendants?

Nothing in the public announcements suggests the deal releases anyone other than 3M. The MDL's personal injury docket names a long list of foam and fluorochemical defendants, including EIDP (the former DuPont), Chemours, Corteva, Tyco Fire Products, BASF and Kidde-Fenwal. DuPont, Chemours and Corteva settled public water system claims in 2023 for $1.185 billion, and Chemours told investors that deal did not resolve personal injury claims. Separately, a multistate fraudulent-transfer fight over the Vylor spinoff is pending before the JPML on transfer to the AFFF MDL.

For plaintiffs, that means a 3M release does not end the case. Claims against the remaining defendants continue, and 3M's resolution may sharpen the pressure on them: the company that historically supplied much of the PFOS-based foam is leaving the courtroom, and the remaining defendants will face an organized plaintiffs' leadership with fewer resources committed to the 3M front.

Why 3M settled now

The timing follows a long build-up. Judge Gergel vacated the first personal injury bellwether trial, a kidney cancer case set for October 20, 2025, by an August 15, 2025 order that pushed the parties toward settlement and required filing of unfiled cases. In 2026 the court ran an aggressive claims-vetting program: a special master appointed in June 2026 recommended dismissal of most claims targeted in the first deficiency motions, and the court largely adopted the report. By October, 3M said vetting was "substantially complete." Defense motions to exclude plaintiffs' experts on liver and thyroid cancer were also pending.

Michael London of Douglas & London credited what he called the "tremendous trial pressure" that looming trials created. From 3M's side, CEO William Brown called the agreement "a significant milestone" that "substantially reduces litigation uncertainty." The company exited PFAS manufacturing at the end of 2025, and the deal aligns its remaining payouts with that exit.

What it means for claimants, PI firms, funders and defendants

For claimants. The decision is individual and will come with a deadline. The core trade is certain, deferred compensation against continued litigation that may soon require early expert proof. Claimants should expect paperwork on diagnosis and exposure regardless of which path they choose.

For plaintiffs' firms. Firms with large inventories face the familiar participation dynamic: walk-away thresholds give the defendant leverage to demand near-total enrollment, and firms with high-volume dockets will be pressed to recommend participation across their whole book. Contingency fee recovery will be spread across up to nine years, and common benefit fund assessments in MDL 2873 will come off the top. Firms should reconcile their inventories against the MDL docket now, since claimants dismissed during CMO 37 vetting may still be eligible.

For funders and lienholders. A back-loaded schedule with nothing in 2027 lengthens the duration of any third-party litigation funding exposure tied to AFFF portfolios. Payments will likely run through a qualified settlement fund, and medical lien resolution, including Medicare, VA and TRICARE interests for the many veterans and service members in the pool, will affect net recoveries and timing.

For remaining defendants. EIDP, Chemours, Corteva, Tyco and others now hold a 3M price point the plaintiffs' bar will cite. They also inherit a docket that has already been vetted, which strips away some of the claim-quality arguments that slow negotiations.

What remains unknown

Several terms that will determine the deal's real value were not public as of November 4: the numeric participation threshold that triggers 3M's walk-away right; the enrollment deadline; the settlement matrix and claims administrator; the precise injury definitions and diagnosis windows; whether turnout-gear claims are inside the program; and the text of the anticipated MDL order for non-participants. Each should surface in the filed agreement or in orders on the MDL 2873 docket in the coming weeks.

FAQ

How much is the 3M PFAS personal injury settlement?

$7.35 billion in nominal dollars paid from 2026 through 2034, with a present value of $5.8 billion. 3M is taking a matching pre-tax charge of about $5.8 billion in the fourth quarter of 2026.

When will AFFF settlement payments be made?

3M will pay $50 million in 2026 and nothing in 2027, so most money flows from 2028 on, with about 20% reserved for 2033 and 2034. Individual payment dates depend on enrollment, claims review and lien resolution.

Who is eligible for the 3M AFFF settlement?

Roughly 115,000 to 120,000 people with AFFF personal injury claims against 3M, inside or outside the MDL, who enroll and sign a full release. Co-lead counsel say six eligible injuries qualify, including kidney and testicular cancer.

Can AFFF plaintiffs opt out of the 3M settlement?

Yes, participation is voluntary. Those who do not join can keep suing, but 3M expects the MDL court to impose evidentiary and timing requirements on them, and a $680 million reserve inside the deal is set aside for remaining and future claims.

Is this the same as the 3M water settlement?

No. The $10.3 billion present-value water deal, approved in March 2024, pays public water systems for PFAS treatment. The November 2026 deal pays individuals for personal injuries.